Tagged with IMI

Switzerland As home to much of Europe’s innovative medicine output and as one of its wealthiest nations per capita, Switzerland has not traditionally been a generic-friendly market. Generics prices are relatively high in a European context and only accounted for 14 percent of total drug sales in 2022. Nevertheless, in recent…

Switzerland Matteo Boggi, General Manager of Fresenius Kabi Switzerland, shares insights into the company’s pivotal role in supporting healthcare professionals as well as critically and chronically ill patients across Switzerland. Boggi highlights Fresenius Kabi’s extensive portfolio in nutrition, medical devices, generic drugs, and biosimilars, while discussing the company’s innovative strategies and…

Switzerland iQone Healthcare has achieved impressive growth under the leadership of CEO Michele Genini, who has guided the company from launching a single biosimilar product in 2016 to building a diverse portfolio of seven. Now part of Celltrion and with a strategic focus on the Swiss market, iQone has become a…

Puerto Rico As president of Puerto Rico’s Colegio de Químicos (CQPR), Dr. José A. Pérez Meléndez is focused on elevating the US territory’s standards of chemistry education and creating a bridge between industry and academia. He remarks on the Colegio’s strategic partnerships and talent retention efforts aimed at solidifying Puerto Rico’s standing…

Mexico Rogerio Peso outlines how Viatris leverages collaborations to address critical healthcare needs in Mexico, combining its strengths with other stakeholders to improve patient outcomes. With a mission to offer high-quality, affordable medicines, Peso also points out how Viatris aligns its portfolio with the healthcare needs of Latin America, addressing gaps…

Mexico Organon’s recently-appointed LAMEX Cluster Head Julio Conejero lays out how Organon is committed to improving women’s health and addressing unmet needs through its portfolio. This mission aligns with the rise of female leadership in Latin America and the broader movement towards women’s empowerment. Now based in Mexico – which accounts…

Switzerland Lucas Schalch of Intergenerika examines the challenges confronting Switzerland’s generic and biosimilar sectors, such as high production costs and changing regulations. Schalch underscores the importance of maintaining a favourable economic environment for these industries.   We must work together to sustain a healthy and competitive market, ensuring that the generic…

China Adept at identifying promising biotechs, Qiming Venture Partners-backed companies saw no less than eight IPOs last year. Managing Partner Nisa Leung provides an update on the firm’s activities in light of current China-US geopolitical tensions and the evolving business development models that have become more focused on licensing innovative drugs…

Mexico Drawing on an industry track record of over 25 years, Fernando Fogarin has recently become the strategic project lead for emerging markets at women’s health specialist Organon. He shares his priorities and the particularities of the Mexican market, discussing the positive impact of the country’s upcoming biosimilars reform; Organon’s efforts…

China Jimmy Wei founded Chime Biologics over 12 years ago with the vision of establishing a global biologics company in China, focusing on biosimilar development and CDMO services. The company’s growth since then has been influenced by the success of other biologics companies like WuXi Biologics and Samsung Biologics, regulatory changes…

Global Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from the pharma companies that manufacture lifesaving antibiotics and antifungals to ensure that patients can get the right medicine when they…

India Mohal Sarabhai, managing director of Ambalal Sarabhai Enterprises Limited (ASE) on transforming his family’s failing century-old business and creating new companies beneath the ASE Holdings umbrella, including a joint venture with Co-Diagnostics, CoSara Diagnostics, that span areas from diagnostics to APIs. He highlights CoSara Diagnostics’ tuberculosis (TB) and human papillomavirus…